In February 2026, Bio-Rad Laboratories reported fourth-quarter 2025 sales of US$693.2 million and net income of US$720 million, marking a return to profitability after a prior-year loss, alongside ...
Q4 2025 Net Sales: $693 million, a 3.9% increase from Q4 2024. Q4 2025 Gross Margin: 49.8% GAAP, 52.5% non-GAAP. Q4 2025 Operating Loss: $119 million, including $173 million in impairment charges. Q4 ...
Bio-Rad Laboratories Inc. (NYSE: BIO and BIOb) today announced the launch of the ChemiDoc MP Digital Imaging System. The imager combines the industry’s best performance with ease of use and is ideal ...
Thank you for standing by. My name is Prila [ph] and I will be your conference operator today. At this time, I would like to welcome everyone to the Bio-Rad Fourth Quarter and Full Year 2024 Results ...
Artisan Partners, an investment management company, released its “Artisan Mid Cap Value Fund” first-quarter 2025 investor letter. A copy of the letter can be downloaded here. The growth stock trade ...
Bio-Rad Laboratories, Inc. (NYSE:BIO) is one of the best debt-free mid-cap stocks to buy according to hedge funds. On February 12, Bio-Rad Laboratories, Inc. (NYSE:BIO) delivered solid fourth-quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results